At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES
In Brief
A Phase 2 clinical trial evaluating bevacizumab [Avastin], cisplatin, and 1 other intervention for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 86 participants across 26 sites.
Detailed Summary
This 2 arm study will evaluate the efficacy and safety of Avastin + gemcitabine, and Avastin + gemcitabine + attenuated doses of cisplatin, as first line treatment in elderly patients with non-squamous non-small cell lung cancer. Patients will be randomised to receive either Avastin 7.5mg/kg iv on day 1 + gemcitabine 1200mg/m2 on days 1-8 of each 3 week cycle, or Avastin 7.5mg/kg iv on day 1 + cisplatin 60mg/m2 on day 1 + gemcitabine 1000mg/m2 on days 1-8 of each 3 week cycle. After 6 cycles of combination therapy, all patients will continue to receive Avastin monotherapy. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.
Study Details
Timeline
Interventions
7.5mg/kg iv on day 1 of each 3 week cycle
60mg/m2 on day 1 of each 3 week cycle
1200mg/m2 on days 1-8 of each 3 week cycle
1000mg/m2 on days 1-8 of each 3 week cycle